Sign In
Buy CLPT
$13.30
+0.93 (+7.52%)
At Close: Jun 03, 2026
ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2020 Results - Earnings Call Transcript
12:20am, Thursday, 13'th Aug 2020
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2020 Results Conference Call August 12, 2020 4:30 PM ET Company Participants Joe Burnett - CEO Harold Hurwitz - CFO Conference Call Participants Sall Yanchus -
ClearPoint Neuro Reports Second Quarter 2020 Results
08:05pm, Wednesday, 12'th Aug 2020
Revenue Reaches $2.5 million Amid COVID-19 PandemicIRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its second fiscal quart
ClearPoint Neuro to Announce Second Quarter 2020 Results on August 12
12:00pm, Thursday, 06'th Aug 2020
Release and Call After Market CloseIRVINE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results fo
How Should Investors React To ClearPoint Neuro's (NASDAQ:CLPT) CEO Pay?
01:25pm, Friday, 17'th Jul 2020
This article will reflect on the compensation paid to Joe Burnett who has served as CEO of ClearPoint Neuro, Inc...
ClearPoint Neuro Reports First Quarter 2020 Results
08:05pm, Tuesday, 12'th May 2020
IRVINE, Calif., May 12, 2020 -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its first fiscal quarter ended March 31, 2020. Total revenues were.
Corrected: ClearPoint Neuro to Announce First Quarter 2020 Results on May 12
08:05pm, Thursday, 07'th May 2020
ClearPoint Neuro, Inc. (CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the mark
ClearPoint Neuro to Announce First Quarter 2020 Results on May 12
12:00pm, Thursday, 07'th May 2020
ClearPoint Neuro, Inc. (CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the mark
Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors
12:10pm, Friday, 17'th Apr 2020
ClearPoint Neuro, Inc. (CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro’s Board of Directors effective immediately. Dr. Klein, Chief Develop
ClearPoint Neuro Provides a COVID-19 Pandemic Update and Announces Preliminary First Quarter 2020 Financial Results
12:00pm, Thursday, 16'th Apr 2020
ClearPoint Neuro, Inc. (CLPT) (the “Company”) today provided an update with respect to the COVID-19 pandemic and announced preliminary financial results for the quarter ended March 31, 2020. “G
Weekly Summary Corporate dividends, name changes, new listings
09:19pm, Friday, 14'th Feb 2020
NEW YORK (AP) — Changes announced in corporate dividends Feb. 10-Feb. 14. INCREASED DIVIDENDS Agnico Eagle Mines Ltd g .20 from .175 Ametek Inc .18 from .14 Auburn National .255 from .25 Avalonbay C
ClearPoint Neuro, Inc. Announces 2020 Revenue Outlook Ahead of Nasdaq Investor Presentation Today
01:55pm, Friday, 14'th Feb 2020
ClearPoint Neuro, Inc. (CLPT) (the “Company”), a leading platform neurosurgery company, today announced a strategic agreement with PTC Therapeutics, Inc. (“PTC”). The scope of the agreement i
DDD, NVTA among premarket gainers
02:27pm, Monday, 13'th Jan 2020
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioP
